CSL agrees USD 1.6 billion Alentis deal. CSL stock sits 13.61 percent below its high

Published on 10/16/2026 at 10:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSL agreed to Alentis' deal on October 5, 2026, paying USD 355 million upfront. CSL stock costs EUR 118.08 on October 16, 2026, below its 52-week high.

Lixudebart deal and key dates

CSL agreed to the Alentis partnership on October 5, 2026, with a USD 355 million upfront payment.
Interim data covered 26 patients in the kidney trial and 41 patients in the liver study.
CSL stock traded at EUR 118.08 at 10:44 a.m. CEST at Lang & Schwarz on October 16, 2026.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL agreed to an exclusive Alentis partnership on October 5, 2026, paying USD 355 million upfront and offering up to USD 1.2 billion in commercial milestones. On ASX, CSL closed at AUD 192.20 on October 16, 2026, 13.61 percent below its AUD 222.47 52-week high. The deal gives the company rights to co-develop and co-promote lixudebart for rare kidney and liver diseases, according to CSL.

What does the deal commit?

CSL will fund completion of the ongoing Phase 2 RENAL trial, a planned Phase 3 study in AAV-RPGN and Phase 2 studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis. The agreement excludes neither development spending nor commercial risk, making the USD 1.2 billion milestone pool conditional rather than an immediate payment.

Global profits would be split 55 percent to CSL and 45 percent to Alentis after commercialization. Reuters reported that the overall deal could be worth up to USD 1.6 billion before development funding.

Why the trial matters

The official announcement cited an interim analysis of 26 patients with AAV-RPGN, with kidney-function improvement measured through eGFR and proteinuria at 24 weeks. A separate Phase 1b FEGATO study involved 41 patients with advanced liver fibrosis and showed improved liver function at six weeks, according to CSL. These are early-stage data, so the commercial value depends on later trials and regulatory progress.

Key dates for CSL investors

CSL's next substantiated corporate date is its annual general meeting on October 27, 2026, at Sofitel Melbourne on Collins. TipRanks reported that the meeting is scheduled for 10:00 a.m. AEDT.

CSL stock stays below its high

CSL's market capitalization was AUD 92.2 billion on October 16, 2026, while its 52-week range was AUD 90.00 to AUD 222.47. The Australian-listed stock closed at AUD 192.20 on that date, separate from the euro indication used for German investors.

CSL was trading at EUR 118.08 at Lang & Schwarz on October 16, 2026 at 10:44 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of CSL stock.